FitLife Brands Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue rose 59% year-over-year to $25.3M, driven by the Irwin acquisition, but net income fell to $1.7M due to higher amortization and interest. Gross margin declined to 37.6%, while Irwin's Amazon business and new MusclePharm SKUs in Kroger stores signal growth opportunities.
Fiscal Year 2025
-
Fourth quarter revenue surged 73% year-over-year, driven by the Irwin acquisition, but gross margin declined due to Irwin's lower historical margins. Ongoing macro and Amazon-related headwinds are pressuring most brands, though Irwin's online growth and debt reduction efforts are bright spots.
-
Q3 revenue rose 47% year-over-year to $23.5M, driven by the Irwin Naturals acquisition and strong MusclePharm growth, but margins declined due to higher protein costs and integration expenses. Consumer softness and Amazon algorithm changes present ongoing risks.
-
Q2 2025 saw a 5% revenue decline and lower net income due to M&A costs, but the Irwin Naturals acquisition positions the business for over $120 million in annual revenue and $20–$25 million adjusted EBITDA. Gross margins are expected to improve as online sales grow.
-
Revenue declined 4% year-over-year to $15.9M, with net income at $2M and adjusted EBITDA down 6%. Legacy FitLife grew, while MRC and MusclePharm saw declines. Gross margins are expected to remain stable, and M&A activity continues to be a strategic focus.
-
The company has transformed from a distressed, wholesale-focused business to a profitable, online-driven operator with a diversified brand portfolio. Strategic acquisitions and disciplined M&A have fueled growth, while management's alignment with shareholders and operational efficiency underpin strong financial performance.
Fiscal Year 2024
-
Revenue and profitability grew strongly in 2024, with online sales driving results and gross margin expansion. Q1 2025 revenue is expected to decline slightly due to tough comparisons, but EBITDA should remain stable. M&A remains a focus, supported by a strong balance sheet.
-
Q3 2024 saw 15% revenue growth, margin expansion, and strong gains in net income and EBITDA. Online sales outperformed wholesale, and new product launches plus M&A flexibility position the company for continued double-digit growth and further deleveraging.